好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Headache, visual loss, and encephalopathy associated with intravenous ozone administration
General Neurology
P6 - Poster Session 6 (11:30 AM-1:00 PM)
15-006

Ozone therapy has been advertised as a treatment for wound healing, cancer, inflammatory conditions, infection, and wellness without scientific evidence. However, reports of neurotoxicity are sparse.

To present a patient with central nervous system toxicity associated with administration of intravenous ozone therapy.

Case report from a tertiary medical center.

A 40-year-old woman presented with visual loss, headache, and confusion. She had been receiving intermittent direct intravenous infusions of oxygen and ozone gas for genital herpes at a private clinic over the past several years. She initially received the ozone therapy via rectal insufflation, which was complicated by colonic perforation. The day prior to presentation, she had a typical intravenous treatment session that was complicated by a one-minute episode of loss of consciousness without a prodrome, followed by blurred vision, confusion, severe headache, and nausea. Her family brought her to the hospital for evaluation when her symptoms persisted the next day. MRI of the brain revealed T2 hyperintensity in the cerebellar white matter. She was admitted for observation and improved with symptomatic treatment over 24 hours. She was discharged home but did not return for follow up.

A syndrome featuring headache, visual loss, and encephalopathy is a potential complication of ozone therapy. Experiments in animal models have shown changes in cerebral vascular endothelial function in association with intravenous ozone therapy. Based on this possible pathogenesis, and resemblance to the clinico-radiographic syndrome, posterior reversible encephalopathy syndrome may represent the diagnosis

Authors/Disclosures
Olivia Tong, MD
PRESENTER
Dr. Tong has received personal compensation for serving as an employee of Alexion Pharmaceuticals.
Matthew S. Robbins, MD, FAAN (Weill Cornell Medicine) Dr. Robbins has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Robbins has received publishing royalties from a publication relating to health care. Dr. Robbins has a non-compensated relationship as a Board of Directors member, 好色先生 Program speaker with American Headache Society that is relevant to AAN interests or activities. Dr. Robbins has a non-compensated relationship as a Board of Directors member, 好色先生 Program speaker with New York State Neurological Society that is relevant to AAN interests or activities. Dr. Robbins has a non-compensated relationship as a Editorial Board Member with Continuum, 好色先生 that is relevant to AAN interests or activities.